Retatrutide + Eloralintide
Retatrutide + Eloralintide is a weekly research vial labeled 12.5 mg, read as 10 mg retatrutide (a GIP / GLP-1 / glucagon receptor agonist) plus 2.5 mg eloralintide (an amylin receptor agonist).
Mixed with 1 mL of water it is dosed in insulin units on retatrutide's own weekly steps: 10 units (retatrutide 1 · eloralintide 0.25 mg), 20, 40 and 80 units at the top (8 · 2 mg).
Best for
Weight-management research interest in pairing a triple incretin agonist with an amylin agonist. Neither compound is approved, and no study has tested the pair.
What to expect
Each compound's trials measured weight change over 48 weeks; no study of the two together exists.
Pairs with
Already an incretin plus an amylin agonist: do not add a GLP-1-class drug or a second amylin agonist (cagrilintide, eloralintide) on top of it.
Once weekly, under the skin, in the morning. At 1 mL of water each unit is 0.1 mg retatrutide + 0.025 mg eloralintide, so the ladder follows retatrutide's steps: 10 units (1 mg + 0.25 mg), 20 (2 + 0.5), 40 (4 + 1) and 80 (8 + 2).
It stops at 80 units — the vial holds 10 mg of retatrutide, so the 12 mg step would take more than a whole vial. Step up no faster than every 4 weeks, and only if progress has stalled.
The split printed is the label read as 10 + 2.5 mg; the one published lot measured 11.07 + 3.18 mg. Specific dosing varies by goal and physician guidance.
- How often
- Weekly
- When
- Morning
- Route
- Subcutaneous
- Vial & water
- 12.5 mg in 1 mL · 10 units ≈ 1 mg Retatrutide + 0.25 mg Eloralintide
- Cycle
- Units, weekly: 10 → 20 → 40 → 80 u, no faster than every 4 weeks, and only if your response has stalled.
The same numbers the goodtides app and the Dose Calc use — a research reference, not a prescription. Responses are individual; research protocols start at the low end.
No approved brand anywhere. Neither compound is approved, and no human trial has tested them together.
Retatrutide is an investigational single peptide that activates the GIP, GLP-1 and glucagon receptors; its phase 2 obesity trial gave 1–12 mg once a week.
Eloralintide is an investigational long-acting amylin receptor agonist; its phase 2 trial gave 1, 3, 6 or 9 mg once a week, and this vial keeps it at or below 2 mg a week. The pairing rests on complementary appetite pathways (incretin and amylin).
No study of this combination exists, in people or animals, and neither compound is approved.
References3
- Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial (N Engl J Med) (retatrutide 1-12 mg weekly)
- Billings LK et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial (Lancet) (eloralintide 1-9 mg weekly)
- Bhattachar S et al. Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept (Diabetes Obes Metab) (eloralintide 1.2-12 mg weekly)
Log every dose, count every vial, and verify your batches — free in the goodtides app.
This page is educational reference material about compounds studied in research settings. It is not medical advice, and nothing here is a recommendation to buy, possess, or use any compound. Research findings described are from published literature; individual compounds may not be approved for human use. Talk to a licensed clinician about anything that affects your health.